Eli Lilly taps blue-chip bond market to fund Morphic acquisition
Indianapolis-based Eli Lilly and Co. is selling U.S. investment-grade bonds on Monday to fund its $3.2 billion acquisition of gut-drug maker Morphic Holding Inc., after recession fears triggered a turbulent week. The company is looking to sell notes in at …